Celldex Therapeutics, Inc.
CLDX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000744218
No open-market purchases or sales by Celldex Therapeutics, Inc. insiders were filed in the last 90 days; 253 institutions reported holding it in 13F filings for Q2 2026, worth $3.16B in total; no superinvestor holds it.
Holders of 5% or more of CLDX
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Celldex Therapeutics, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Wellington Management Group LLP | 13G/A | 12.20%8.08M shares | +1.10 ppfrom 11.10% | Feb 6, 20238 filings | Feb 10, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.30%4.82M shares | −1.00 ppfrom 8.30% | Feb 5, 20252 filings | Apr 17, 2025 | SEC |
| Kynam Capital Management, LP | 13G/A | 6.78%0 shares | −1.99 ppfrom 8.77% | Feb 14, 20245 filings | Aug 14, 2026 | SEC |
| Price T Rowe Associates Inc | 13G | 6.00%4.69M shares | +2.40 ppfrom 3.60% | Feb 14, 20253 filings | Aug 14, 2026 | SEC |
| FMR LLC | 13G/A | 5.60%3.75M shares | −1.70 ppfrom 7.30% | Oct 12, 20217 filings | May 6, 2026 | SEC |
| Vanguard Capital Management LLC | 13G | 5.17%3.45M shares | New | Apr 29, 20261 filing | Apr 29, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
68 Schedule 13D and 13G filings on Celldex Therapeutics, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Jun 10, 2022 | Viking Global Investors LPSuperinvestorViking Global Investors | 13GOld format | – | New | – | SEC |
| Feb 14, 2022 | Redmile Group, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 14, 2022 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2022 | State Street Corp | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | Vanguard Group Inc | 13GOld format | – | New | – | SEC |
| Feb 9, 2022 | FMR LLC | 13G/AOld format | – | – | – | SEC |
| Feb 4, 20224:12 PM ET | BlackRock Inc. | 13GOld format | – | New | – | SEC |
| Jan 18, 2022 | Cowen Financial Products LLC | 13G/AOld format | – | – | – | SEC |
| Jan 14, 2022 | Cowen Financial Products LLC | 13G/AOld format | – | – | – | SEC |
| Oct 12, 2021 | FMR LLC | 13GOld format | – | New | – | SEC |
| Feb 25, 2021 | Cowen Financial Products LLC | 13GOld format | – | New | – | SEC |
| Feb 16, 2021 | Redmile Group, LLC | 13GOld format | – | New | – | SEC |
| Feb 12, 2021 | RTW Investments, LP | 13G/AOld format | – | – | – | SEC |
| Feb 12, 2021 | Ikarian Capital, LLC | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Biotechnology Value Fund L P | 13G/AOld format | – | – | – | SEC |
| Feb 11, 2021 | Adage Capital Partners GP, L.L.C. | 13G/AOld format | – | – | – | SEC |
| Feb 10, 2021 | Renaissance Technologies LLC | 13G/AOld format | – | – | – | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Celldex Therapeutics, Inc. shares.
No Form 144 notices for Celldex Therapeutics, Inc. are on file.